Mr. Tim Gallagher RPh

Executive Vice President of Pharmacy Operations , ASTRUP DRUG, INC.

Member of the Healthcare Council

Council Member Biography

Tim Gallagher, RPh, is the Executive Vice President of Pharmacy Operations at Astrup Drug in Minnesota, since 1999. Mr. Gallagher manages all aspects of pharmacy operations for the company. He has been a practicing pharmacist for over 25 years in both the chain and independent community pharmacy setting and has also been a consultant pharmacist in the institutional or long-term care industry. Mr. Gallagher is active in several professional pharmacy organizations at both the state and national level. He is a member of the Board of Directors and Past President of the Minnesota Pharmacists Association, where he chaired the Public Affairs Committee, which develops and implements polices for the Association and oversees all legislative activities. Mr. Gallagher sat on the Medicaid Payment Reform Advisory Committee for the Minnesota Department of Human Services. He currently sits on the Minnesota E-Health Advisory Committee for the MN Department of Health. (This is me - Update Profile)

Employment History

1999 - Unspecified: Executive Vice President of Pharmacy Operations , ASTRUP DRUG, INC.
1994 - 1999: Pharmacy Manager, Sterling Drug

GLG News^SM Analyses by Tim Gallagher(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.

Should We Treat Colds In Children?

November 1, 2007

Analysis of:Cough-Medicine Dilemma Widens | online.wsj.com

An FDA advisory panel recently voted to stop the recommendation of otc cough and cold products in children less than 12 years of age. For decades parents have administered otc cough and could products to infants and young children. Even the FDA Advisory Committee had dissention amongst their members, voting 13 to 9 in favor of the change in the long standing treatment protocol of children's colds.

Exit Exubera

October 22, 2007

Analysis of:Pfizer Abandons Exubera, Posts 77% Earnings Decline | online.wsj.com

Pfizer failed miserably in its attempt to provide diabetic patients with an easy-to-use inhaled insulin as an alternative to injectable insulin. A product they projected would generate sales of $2 billion a year recorded a disappointing $12 million in sales this year. CEO Kindler said he decided to pull the product to spend shareholders' money more wisely. Perhaps he should have thought about that a little sooner.

New Dose For Old Drug

October 1, 2007

Analysis of:FDA approves SOMA 250 mg | www.pipelinereview.com

The FDA recently approved a 250mg Soma® tablet manufactured by MedPointe Pharmaceuticals as a new recommended dose for the treatment of painful musculoskeletal problems such as backache. The drug is not new, in fact it has been around for nearly 50 years, first receiving FDA approval in 1959. The same drug was available at one time in a 250mg capsule but was discontinued.

FDA Approval Of FluMist For Use In Young Children Boon For MedImmune

September 24, 2007

Analysis of:FDA Okays FluMist Vaccine For Young Children | www.medicalnewstoday.com

The FDA recently approved the expanded use of FluMist, the only nasal spray influenza vaccine, in children 2 to 5 years of age. Each year in the U.S up to 60 million Americans get the flu according to the CDC. The U.S. CDC recommends all children aged 6 to 59 months be vaccinated against the flu. FluMist uses a live, attenuated virus rather than an inactive virus. A recent study indicates that the nasal spray may be more effective than the injection.

What Effect Will The Removal Of CFC Inhalers Have On The Health Care Market?

September 17, 2007

Analysis of:CFC-free inhalers for asthma patients. | timesofindia.indiatimes.com

The transition from albuterol inhalers containing CFC propellants to those containing HFA propellants has certain ramifications for the health care market. The phaseout of existing generic albuterol inhalers has caused a constriction in the market and an increase in the cost of these products. Newer ozone-friendly products represent a significantly higher cost of therapy for patients. Some patients may cut back on the use of these products or forgo their use altogether. This may lead to more severe acute asthma attacks, more emergency room visits and hospitalizations, and increased health care costs.

View All GLG News ^SM Analyses by Tim Gallagher